Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization

Abstract

The specimens of ductal carcinoma in situ (DCIS) with early invasion, and specimens collected by core needle biopsy (CNB) tend to contain limited amount of invasive component, so it is imperative to explore a new technique which can assess HER2 gene status accurately for the limited invasive cancer component in these specimens. Dual staining technique of combining immunohistochemistry (IHC) for myoepithelial cells and single or dual probe chromogenic in situ hybridization (CISH) for HER2 gene was performed on routinely processed paraffin sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 10 had fluorescence in situ hybridization (FISH)-confirmed amplification of HER2 and 10 had FISH-confirmed non-amplification of HER2. We successfully detected HER2 genetic signals and myoepithelial IHC markers (SMM-HC or CK5/6) simultaneously on a single section in all 20 specimens. Myoepithelial markers and HER2 signals detected by dual staining assay were consistent with those by individual technique performed alone. HER2 gene amplification results determined by dual staining assay were 100% consistent with those of FISH. Dual staining technique which allows simultaneous detection of myoepithelial marker protein and cancerous HER2 gene is feasible, and it has potential to be used in clinical practice for effective determination of HER2 amplification in limited invasive component.

Keywords

human epidermal growth factor receptor 2 / chromogenic in situ hybridization / immunohistochemistry

References

[1] RossJS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect, 2009, 22(2): 93-106

[2] LayfieldLJ, LewisC. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol, 2007, 29(4): 239-243

[3] BurkhardtL, GrobTJ, HermannI, et al.. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat, 2010, 123(3): 757-765

[4] ParkK, HanS, KimHJ, et al.. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology, 2006, 48(6): 702-707

[5] WolffAC, HammondME, SchwartzJN, et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25(1): 118-145

[6] ErnsterVL, Ballard-BarbashR, BarlowWE, et al.. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst, 2002, 94(20): 1546-1554

[7] ClarkSE, WarwickJ, CarpenterR, et al.. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer, 2011, 104(1): 120-127

[8] PimientoJM, LeeMC, EspositoNN, et al.. Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion. J Oncol Pract, 2011, 7(5): 309-313

[9] LeongAS, SormunenRT, VinyuvatS, et al.. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma: A comparison of eight contemporary grading systems. Am J Clin Pathol, 2001, 115(5): 709-718

[10] BougheyJC, GonzalezRJ, BonnerE, et al.. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist, 2007, 12(11): 1276-1287

[11] HwangCC, PintyeM, ChangLC, et al.. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology, 2011, 59(5): 984-992

[12] MollerupJ, HenriksenU, MullerS, et al.. Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization. BMC Clin Pathol, 2012, 12(12): 3

[13] GongY, SweetW, DuhYJ, et al.. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol, 2009, 131(4): 490-497

[14] MayrD, HeimS, WeyrauchK, et al.. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology, 2009, 55(6): 716-723

[15] IsolaJ, TannerM, ForsythA, et al.. Interlaboratory comparison of HER-2 oncogene amplification as detected by. Cancer Res, 2004, 10(14): 4793-4798

[16] Penault-LlorcaF, BilousM, DowsettM, et al.. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol, 2009, 132(4): 539-548

[17] LambrosMB, NatrajanR, Reis-FilhoJS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol, 2007, 38(8): 1105-1122

[18] MadridMA, LoRW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res, 2004, 6(5): R593-R600

[19] NittaH, Hauss-WegrzyniakB, LehrkampM, et al.. Development of automated bright-field double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol, 2008, 22(3): 41

[20] García-CaballeroT, GrabauD, GreenAR, et al.. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology, 2010, 56(4): 472-480

[21] LerwillMF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol, 2004, 28(8): 1076-1091

[22] NiR, MulliganAM, HaveC, et al.. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol, 2007, 15(3): 316-324

[23] Downs-KellyE, PettayJ, HicksD, et al.. Analytical validation and interobserver reproducibility of EnzMet Gene-Pro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol, 2005, 29(11): 1505-1511

[24] EllisZO, CornelisseCJ, SchinittSJ, et al.. TavassoliFA, DevileeP, et al.. Invasive breast carcinoma. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, 2003, Lyon, IARC Press, 20

[25] HilsonJB, SchnittSJ, CollinsLC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol, 2009, 33(2): 227-232

[26] MoriyaT, KozukaY, KanomataN, et al.. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology, 2009, 41(1): 68-76

[27] LermaE, BarnadasA, PratJ. Triple negative breast carcinomas: similarities and differences with basal like carcinomas. Appl Immunohistochem Mol Morphol, 2009, 17(6): 483-494

[28] SuttonLM, HanJS, MolbergKH, et al.. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol, 2010, 134(5): 782-787